Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Down 5% – Should You Sell?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) dropped 5% on Monday . The stock traded as low as $126.19 and last traded at $126.69. Approximately 135,497 shares were traded during trading, a decline of 89% from the average daily volume of 1,241,097 shares. The stock had previously closed at $133.34.

Analysts Set New Price Targets

A number of analysts have issued reports on the company. Cantor Fitzgerald raised Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their target price for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Barclays cut their target price on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Citigroup decreased their price objective on Sarepta Therapeutics from $176.00 to $160.00 and set a “neutral” rating on the stock in a report on Thursday, August 8th. Jefferies Financial Group assumed coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 price objective for the company. Finally, UBS Group upped their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, twenty have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus target price of $175.77.

Sarepta Therapeutics Stock Performance

The stock has a fifty day moving average of $122.50 and a 200-day moving average of $131.48. The firm has a market capitalization of $12.13 billion, a P/E ratio of 101.42 and a beta of 0.81. The company has a quick ratio of 3.03, a current ratio of 3.84 and a debt-to-equity ratio of 0.93.

Hedge Funds Weigh In On Sarepta Therapeutics

Several hedge funds have recently made changes to their positions in the business. Innealta Capital LLC bought a new stake in shares of Sarepta Therapeutics in the second quarter worth $31,000. Nkcfo LLC acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at $43,000. Sunbelt Securities Inc. lifted its position in Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company’s stock worth $35,000 after buying an additional 232 shares in the last quarter. Huntington National Bank boosted its stake in shares of Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company’s stock worth $36,000 after buying an additional 175 shares during the last quarter. Finally, Riggs Asset Managment Co. Inc. grew its holdings in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company’s stock valued at $47,000 after acquiring an additional 75 shares in the last quarter. 86.68% of the stock is owned by institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.